Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline.


Pentoxifylline is a tumor necrosis factor-α (TNF-α) inhibitor that also attenuates the immune response and decreases tissue inflammation. The association of pentoxifylline with antimony improves the cure rate of mucosal and cutaneous leishmaniasis. In this randomized and double blind pilot trial, cure rate was higher, although not significant, in patients… (More)
DOI: 10.4269/ajtmh.12-0729